Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

Trial Profile

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs GPX 150 (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors Gem Pharmaceuticals
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 According to Gem Pharmaceuticals media release, the company announced preliminary results of this trial at the annual meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top